β-amyloid (Aβ) is a hydrophobic peptide with an intrinsic tendency to self-assemble into
aggregates. Among various aggregates, Aβ oligomer is widely accepted as the leading
neurotoxin in the progress of Alzheimer's disease (AD) and is considered to be the crucial
event in the pathogenesis of AD. Therefore, Aβ oligomer inhibitors might prevent
neurodegeneration and have the potential to be developed as disease-modifying treatments
of AD. However, different formation protocols of Aβ oligomer might lead to oligomers with …